UBS Initiates Coverage on Novo Nordisk (NVO) with a Neutral
More News related to NVO
- Paladin Reports Record Third Quarter 2009 Financial Results
- Novo Nordisk is Changing Possibilities in Hemophilia
- New Study Finds Significant Inconsistency With How Diabetes Quality of Care is Measured
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
UBS initiates coverage on Novo Nordisk (NYSE: NVO) with a Neutral.
Novo Nordisk A/S is a Denmark-based healthcare company. The Company provides diabetes care and has diabetes product portfolio in the industry, including insulin delivery systems.
Related Categories
New CoverageStocks Mentioned
+0.49Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
